Posted by Michael Wonder on 16 Apr 2025
US FDA grants interchangeable designation to Yuflyma (adalimumab-aaty), Celltrion's biosimilar to Humira (adalimumab)
14 April 2025 - Interchangeable designation of Yuflyma is supported by positive data from the Phase 3 interchangeability study in patients with moderate to severe plaque psoriasis
Celltrion today announced that the US FDA has designated Yuflyma (adalimumab-aaty), as an interchangeable biosimilar to Humira (adalimumab).
